Analyst rates Cabaletta Bio a Buy at a $276 million valuation below $299 million cash, though one IEC-HS case could drive 80% or more downside.
Cabaletta Bio is rated Buy, trading 40% below its $2.41 pipeline value despite a single-asset risk profile. Click here to read this CABA stock update.
Detailed price information for Cabaletta Bio Inc (CABA-Q) from The Globe and Mail including charting and trades.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Meetings with investors on Tuesday, September 8, 2026, in Boston, MA.2026 Cantor Global Healthcare Conference: M
This is the newest page. Registered accounts read further back.